Literature DB >> 22340214

Autologous bone marrow stem cell transplantation for the treatment of type 2 diabetes mellitus.

Li Wang1, Shi Zhao, Hong Mao, Ling Zhou, Zhong-Jing Wang, Hong-Xiang Wang.   

Abstract

BACKGROUND: Autologous peripheral stem cell transplantation was first reported in 2007 to treat type 1 diabetes mellitus (DM) and achieved encouraging effect, but whether similar outcome can be achieved in type 2 DM is not well demonstrated. The objective of this study was to determine the effect of combination of autologous bone marrow stem cell transplantation (BMT) and hyperbaric oxygen treatment on type 2 DM.
METHODS: The study involved 31 patients with type 2 DM (aged 33 to 62 years) from January 2009 to January 2011 in the Central Hospital of Wuhan, China. Clinical variables (body mass index, duration of DM, insulin requirement, oral hypoglycemic drugs, time free from insulin, time free from oral drugs) and laboratory variables (hemoglobin A1c (HbA1c)), mononuclear cells infused, and C-peptide in four time points) were assessed. Purified bone marrow stem cells were infused into major pancreatic arteries. Follow-up was performed at the 30, 90, 180, 360, 540 and 720 days (mean 321 days) after BMT.
RESULTS: Mean HbA1c values showed a significant reduction during follow-up in all patients after BMT. It decreased by more than 1.5% (from 8.7% to 7.1%) as quickly as at 30 days after BMT. Afterwards mean HbA1c fluctuated between plus or minus 0.5% until 24 months rather than declined continuously. At 90 days after the combined therapy C-peptide increased significantly compared with baseline (P < 0.0001). But in other time points C-peptide was similar with baseline data (P > 0.3). All patients had insulin and/or oral hypoglycemic drugs reduced to different levels. The dose of insulin of 7 patients (7/26, 27%) reduced for a period of time after BMT.
CONCLUSIONS: Combined therapy of intrapancreatic BMT and hyperbaric oxygen treatment can improve glucose control and reduce the dose of insulin and/or oral hypoglycemic drugs in type 2 DM patients, but it only improve pancreatic β-cell function transiently. Further randomized controlled clinical trials involved more patients will be required to confirm these findings and the mechanism needs to be illustrated deeply.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22340214

Source DB:  PubMed          Journal:  Chin Med J (Engl)        ISSN: 0366-6999            Impact factor:   2.628


  15 in total

1.  Bone marrow derived stem cell therapy for type 2 diabetes mellitus.

Authors:  Tarek Wehbe; Nassim Abi Chahine; Salam Sissi; Isabelle Abou-Joaude; Louis Chalhoub
Journal:  Stem Cell Investig       Date:  2016-12-06

Review 2.  Current progress of human trials using stem cell therapy as a treatment for diabetes mellitus.

Authors:  Shuk Kei Cheng; Elisse Y Park; Andjela Pehar; Alexandra C Rooney; G Ian Gallicano
Journal:  Am J Stem Cells       Date:  2016-10-20

3.  Bone marrow mononuclear cell angiogenic competency is suppressed by a high-salt diet.

Authors:  Jamie R Karcher; Andrew S Greene
Journal:  Am J Physiol Cell Physiol       Date:  2013-11-20       Impact factor: 4.249

4.  Therapeutic efficacy and biodistribution of allogeneic mesenchymal stem cells delivered by intrasplenic and intrapancreatic routes in streptozotocin-induced diabetic mice.

Authors:  Juliana Navarro Ueda Yaochite; Carolina Caliari-Oliveira; Lucas Eduardo Botelho de Souza; Lourenço Sbragia Neto; Patrícia Vianna Bonini Palma; Dimas Tadeu Covas; Kelen Cristina Ribeiro Malmegrim; Julio César Voltarelli; Eduardo Antônio Donadi
Journal:  Stem Cell Res Ther       Date:  2015-03-14       Impact factor: 6.832

5.  Efficacy and safety of autologous bone marrow derived hematopoietic stem cell transplantation in patients with type 2 DM: A 15 months follow-up study.

Authors:  Anil Bhansali; Vimal Upreti; Rama Walia; Vivek Gupta; Shobhit Bhansali; R R Sharma; Sandeep Grover; Neelam Marwaha; Niranjan Khandelwal
Journal:  Indian J Endocrinol Metab       Date:  2014-11

Review 6.  Stem cell transplantation improves aging-related diseases.

Authors:  Susumu Ikehara; Ming Li
Journal:  Front Cell Dev Biol       Date:  2014-05-02

Review 7.  Induced pluripotent stem cell potential in medicine, specifically focused on reproductive medicine.

Authors:  Olivier Botman; Christine Wyns
Journal:  Front Surg       Date:  2014-03-24

8.  Bone marrow stem cell as a potential treatment for diabetes.

Authors:  Ming Li; Susumu Ikehara
Journal:  J Diabetes Res       Date:  2013-04-10       Impact factor: 4.011

9.  Administration of BMSCs with muscone in rats with gentamicin-induced AKI improves their therapeutic efficacy.

Authors:  Pengfei Liu; Yetong Feng; Chao Dong; Dandan Yang; Bo Li; Xin Chen; Zhongjun Zhang; Yi Wang; Yulai Zhou; Lei Zhao
Journal:  PLoS One       Date:  2014-05-13       Impact factor: 3.240

Review 10.  Mesenchymal stem cell therapy in type 2 diabetes mellitus.

Authors:  Li Zang; Haojie Hao; Jiejie Liu; Yijun Li; Weidong Han; Yiming Mu
Journal:  Diabetol Metab Syndr       Date:  2017-05-15       Impact factor: 3.320

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.